glucagon has been researched along with olanzapine in 7 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (olanzapine) | Trials (olanzapine) | Recent Studies (post-2010) (olanzapine) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 6,339 | 1,340 | 2,383 |
| Protein | Taxonomy | glucagon (IC50) | olanzapine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.097 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.155 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.047 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.04 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.541 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.768 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.118 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.047 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.421 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.531 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.392 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.072 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.173 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.092 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.038 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.021 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.047 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 1.033 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.013 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.078 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.057 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.013 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.158 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.2028 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Joye, F; Marion, F; Michoux, I; Orrillard, M; Parisot, R | 1 |
| Baptista, T; Beaulieu, S; Contreras, Q; de Mendoza, S; Galeazzi, T; Lacruz, A; Rangel, N; Sandia, I; Vargas, D | 1 |
| Shepherd, PR; Smith, GC; Vickers, MH | 1 |
| Ikeda, H; Ikegami, M; Ishikawa, Y; Kai, M; Kamei, A; Kamei, J; Ohashi, T; Ohsawa, M | 1 |
| Ishiwata, Y; Nagata, M; Nakajima, M; Negishi, K; Takahashi, H; Takahashi, Y; Yasuhara, M | 1 |
| Castellani, LN; Charron, MJ; Peppler, WT; Sutton, CD; Whitfield, J; Wright, DC | 1 |
| Hahn, MK; McKie, GL; Medak, KD; Shamshoum, H; Wright, DC | 1 |
1 trial(s) available for glucagon and olanzapine
| Article | Year |
|---|---|
Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; C-Reactive Protein; Double-Blind Method; Female; Fibrinogen; Glucagon; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Male; Metabolic Syndrome; Metformin; Middle Aged; Olanzapine; Schizophrenia; Sex Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2007 |
6 other study(ies) available for glucagon and olanzapine
| Article | Year |
|---|---|
[Severe intoxication probably from olanzapine (Zyprexa). Beneficial effect of glucagon].
Topics: Adult; Alprazolam; Antipsychotic Agents; Benzodiazepines; Bradycardia; Carbamazepine; Disseminated Intravascular Coagulation; Drug Therapy, Combination; Gastrointestinal Agents; Glucagon; Humans; Hypothermia; Infusions, Intravenous; Male; Methotrimeprazine; Olanzapine; Pirenzepine; Schizophrenia; Shock | 1999 |
Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Weight; Diet, High-Fat; Food Preferences; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Liver; Male; Obesity; Olanzapine; Rats; Schizophrenia; Weight Gain | 2011 |
Olanzapine induces glucose intolerance through the activation of AMPK in the mouse hypothalamus.
Topics: AMP-Activated Protein Kinases; Animals; Benzodiazepines; Enzyme Activation; Glucagon; Glucose; Glucose Tolerance Test; Homeostasis; Hypothalamus; Insulin; Male; Mice; Mice, Inbred ICR; Olanzapine; Phosphorylation; Protein Kinase Inhibitors | 2013 |
Mechanism Underlying Induction of Hyperglycemia in Rats by Single Administration of Olanzapine.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Corticosterone; Epinephrine; Glucagon; Histamine; Hyperglycemia; Injections, Intravenous; Insulin; Male; Models, Biological; Olanzapine; Propranolol; Rats, Wistar | 2016 |
Glucagon receptor knockout mice are protected against acute olanzapine-induced hyperglycemia.
Topics: Animals; Benzodiazepines; Blood Glucose; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Glucose Tolerance Test; Homeostasis; Hyperglycemia; Insulin; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Olanzapine; Receptors, Glucagon | 2017 |
Fasting or the short-term consumption of a ketogenic diet protects against antipsychotic-induced hyperglycaemia in mice.
Topics: 3-Hydroxybutyric Acid; Animals; Antipsychotic Agents; Blood Glucose; Diet, Ketogenic; Esters; Fasting; Glucagon; Hyperglycemia; Insulin; Ketone Bodies; Ketones; Mice; Olanzapine | 2022 |